ACC
Spotlight on Lp(a) Risks, Low Testing Prevalence, and Potential Treatments at Cardiology Meeting
Premium
At ACC's annual meeting, there was a big focus on educating doctors about Lp(a) testing and its role in heart disease as new drugs advance in clinical trials.
Scores focused on the biochemical pathways associated with disease and pairing these scores with other risk assessments could improve predictive value, the data showed.
Researchers at ACC's annual meeting presented data from studies on genotype-guided care for patients who had undergone percutaneous coronary interventions.
Ionis is preparing to submit a new drug application for an investigational treatment for chylomicronemia syndrome that targets APOC3 mRNA.
Combination of Polygenic, Social, Clinical Factors Improve Prediction of Heart Disease Risk
A model of these three measures improved heart disease risk predictions over any one measure, researchers reported at the American College of Cardiology meeting.